<DOC>
	<DOCNO>NCT00967382</DOCNO>
	<brief_summary>The TIPPS trial seek determine safety effectiveness low-molecular-weight heparin ( LMWH ) , anticoagulant , prevent placenta mediate pregnancy complication venous thromboembolism ( VTE ) woman thrombophilia . Thus , principal research question : LMWH prevent thrombosis leg vein , pulmonary artery placental vessel , thereby reduce risk deep vein thrombosis , pulmonary embolism ( PE ) , intrauterine growth restriction ( IUGR ) , preeclampsia , miscarriage stillbirth ?</brief_summary>
	<brief_title>TIPPS : Thrombophilia Pregnancy Prophylaxis Study</brief_title>
	<detailed_description>TIPPS multicentre , multi-national open-label randomize controlled clinical trial . Two hundred eighty-four thrombophilic woman risk VTE placenta mediate pregnancy complication recruit . Patients require anticoagulant prophylaxis pregnancy ( judged local investigator ) participate TIPPS eligible trial . The study consist five period : screening , randomization , antenatal follow-up , labour delivery , post-partum follow-up . Eligible consent patient assign one two group ( treatment control ) , stratify gestational age randomization : le 8 week , 8 week +1 day 12 week , 12 week +1 day 19 week + 6 day . Treatment Group - Subjects randomized treatment group receive daily injection dalteparin ante-natal period . They teach self-administer sub-cutaneous injection dalteparin 5000 International unit ( IU ) daily ( o.d . ) gestational week 20 , twice daily ( bid ) 37 week gestation onset labour . Control Group- Subjects randomize control receive identical obstetrical care follow-up , ante-natal dalteparin . Visit Schedule Subject evaluate study eligibility consent sign baseline assessment complete . Randomization do within 7 day baseline visit . All patient see person first follow-up visit 7-9 day randomization . Subsequent visit base gestational age fetus follow : - Monthly ( +/- 1 week ) gestational week 8 28 - - Every 2 week ( +/- 1 week ) gestational week 28 34 - Every week gestational week 35 delivery . The following visit require in-person day 7-9 gestational week 12 , 20 , 28 , 32 and/or 36 6 week post-partum coincide safety blood draws hematology biochemistry regardless treatment allocation . The remain visit do person phone call : gestational week 8 , 16 , 24 , 30 , 34 , 35 , 37 , 38 , 39 40 . If available , result hematology biochemistry do gestational age 8 , 16 , 24 40 record . At visit , weight blood pressure measurement record subject monitor study progress , study outcome , adverse event ( AEs ) , concomitant medication . Subjects randomize receive dalteparin compliance assess monthly visit . Subjects require complete patient injection diary ask bring in-person-visits . The diary collect completion study participation . Labour delivery : outcome AEs assess review subject ' medical record . If available , result blood drawn hematology biochemistry record . Data pertain labour delivery , well foetal weight health birth , document . For subject randomize receive dalteparin , date time last injection note . During six-week postpartum period , subject receive dalteparin 5,000 IU o.d . VTE prophylaxis . Subjects randomize control teach self-administer subcutaneous injection prior start postpartum injection . Subjects ask complete patient injection diary return final visit . The final study visit occur 6 week post-partum ( +/- 1week ) early termination ; visit study progress , study outcome , adverse event , result blood drawn hematology biochemistry compliance study drug document .</detailed_description>
	<mesh_term>Pregnancy Complications</mesh_term>
	<mesh_term>Thrombophilia</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>One following : Previous preeclampsia Previous unexplained intrauterine growth restriction Previous recurrent miscarriage : three ( 3 ) unexplained miscarriage le 10 week gestation ; two ( 2 ) unexplained fetal loss 10 16 week gestation ; one ( 1 ) unexplained fetal loss great 16 week gestation Previous abruptio placenta Previous personal history VTE : Previous document secondary proximal VTE , Previous document calfvein thrombosis ( idiopathic secondary ) , Previous superficial phlebitis First degree relative symptomatic thrombophilia Pregnancy &gt; 4weeks gestation &lt; 20 week gestation Thrombophilia : Two abnormal test , normal test 3.1 Protein S 3.2 Protein C 3.3 Antithrombin Two positive test 3.4 Anticardiolipin immunoglobulin M ( IgM ) ( &gt; 30 U/ml ) 3.5 Anticardiolipin immunoglobulin G ( IgG ) ( &gt; 30 U/ml ) 3.6 Antib2 glycoprotein IgG ( &gt; 20 U/ml ) 3.7 Antib2 glycoprotein IgM ( &gt; 20 U/ml ) 3.8 Lupus anticoagulant One positive test 3.9 Factor V Leiden ( heterozygous homozygous ) 3.10Prothrombin gene defect ( heterozygous homozygous ) Less 4 week gestation great 20 week gestation No confirm thrombophilia Contraindication heparin therapy History heparin induce thrombocytopenia Platelet count less 100,000 109/L History osteoporosis steroid use Actively bleed Documented peptic ulcer within 6 week Heparin , bisulfite fish allergy Severe hypertension ( Systolic Blood Pressure &gt; 200mmhg and/or Diastolic Blood Pressure &gt; 120mmHg ) Serum creatinine great 80 umol/L ( 1.3mg/dl ) abnormal 24 hour urine creatine clearance ( &lt; 30ml/min ) Severe hepatic failure ( INR &gt; 1.8 ) Geographic inaccessibility Need anticoagulant , discretion investigator limit : Recurrent fetal loss phospholipid antibody syndrome Prior idiopathic proximal VTE : History idiopathic deep venous thrombosis ( DVT ) pulmonary embolism ( PE ) treat anticoagulant ( &gt; 1 month heparin warfarin ) inferior vena cava ( IVC ) interruption ; Idiopathic VTE occur outside follow period : antepartum , postpartum , oral contraceptive use , surgery , immobilization , cast , malignancy Mechanical heart valve Legal low age limitation ( country specific ) Prior participation TIPPS Unable/unwilling provide inform consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Pregnancy</keyword>
	<keyword>Thrombophilia</keyword>
	<keyword>High-risk pregnancy</keyword>
	<keyword>LMWH prophylaxis</keyword>
	<keyword>Placenta mediate pregnancy complication</keyword>
</DOC>